Lordick, F. and Schuler, M. and Al-Batran, S-E. and Zvirbule, Z. and Manikhas, G. and Rusyn, A. and Vinnyk, Y. and Vynnychenko, I. and Fadeeva, N. and Nechaeva, M. and Dudov, A. and Gotovkin, E. and Pecheniy, A. and Bazin, I. and Bondarenko, I. and Melichar, B. and Huber, C. and Sahin, U. and Türeci, Ö. (2016) Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Annals of Oncology, 27 (supp_9). mdw582.001. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
|
Text
Article Navigation.pdf Download (381kB) | Preview |
Abstract
Background: Claudin(CLDN)18.2 is a stomach specific tight junction protein. The chimeric monoclonal anti-CLDN18.2 antibody IMAB362 potently activates complement and antibody dependent cellular cytotoxicity. FAST investigated CLDN18.2 tumor expression and therapy with IMAB362 in combination with first line chemotherapy in pts with advanced gastric and GEJ cancer. Methods: Pts with advanced gastric and GEJ cancer were centrally evaluated for CLDN18.2 by immunohistochemistry (CLAUDETECT18.2® Kit). CLDN18.2 expression of ≥ 2+ in ≥ 40% tumor cells was defined positive. Eligible pts required CLDN18.2+ tumors, an ECOG PS of 0–1, and no medical need for trastuzumab treatment.
| Item Type: | Article |
|---|---|
| Subjects: | Oncology |
| Divisions: | Departments > Department of Oncology and Medical Radiology |
| Depositing User: | Елена Шрамко |
| Date Deposited: | 19 Sep 2017 13:46 |
| Last Modified: | 19 Sep 2017 13:47 |
| URI: | http://repo.dma.dp.ua/id/eprint/1958 |
Actions (login required)
 |
View Item |
